![1️⃣st publication from the 🇦🇪 in LANCET ONCOLOGY, the highest impact factor oncology journal. | Cancer Care Center UAE 1️⃣st publication from the 🇦🇪 in LANCET ONCOLOGY, the highest impact factor oncology journal. | Cancer Care Center UAE](https://www.cancercarespecialtiesmena.com/wp-content/uploads/2020/09/M15__1599547915_60.254.64.153.jpg)
1️⃣st publication from the 🇦🇪 in LANCET ONCOLOGY, the highest impact factor oncology journal. | Cancer Care Center UAE
![Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study - The Lancet Oncology Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study - The Lancet Oncology](https://www.thelancet.com/cms/asset/5bf67cd5-b61e-4437-ab35-bb60cd506794/gr1.jpg)
Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study - The Lancet Oncology
![Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment - The Lancet Oncology Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment - The Lancet Oncology](https://www.thelancet.com/cms/asset/d71212ca-4455-4b9b-a416-2fdae6a43133/gr1.jpg)
Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment - The Lancet Oncology
![The Lancet more than doubles its impact factor, eclipsing NEJM for the first time ever – Retraction Watch The Lancet more than doubles its impact factor, eclipsing NEJM for the first time ever – Retraction Watch](https://retractionwatch.com/wp-content/uploads/2022/06/lancet.jpeg)
The Lancet more than doubles its impact factor, eclipsing NEJM for the first time ever – Retraction Watch
![Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study - The Lancet Oncology Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/20d045e5-e754-4e83-be70-676130b79c2b/gr1.jpg)